Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 1/20 | 0.58 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.58 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701656 | 1.00 | ABCC9 (0.58) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4704986 | 0.99 | ABCC9 (0.57) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4704982 | 0.99 | ABCC9 (0.57) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4701935 | 0.92 | ABCC9 (0.48) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4701943 | 0.92 | ABCC9 (0.48) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4757847 | 0.92 | POLB (0.51) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4757858 | 0.92 | POLB (0.51) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4700802 | 0.91 | POLB (0.54) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4260603 | 0.91 | POLB (0.54) | ABCC9ABCC8KCNJ11POLBMAPT | |
| SCHEMBL4699975 | 0.91 | ABCC9 (0.50) | ABCC9ABCC8KCNJ11POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335902-B1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1335902-B1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1335902-A1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-6472413-B2 | FOR THERAPY OF VAGAL DYSFUNCTION IN THE HEART, IMPROVING CARDIAC FUNCTION, THERAPY OF PERSON SUSCEPTIBLE TO CARDIAC DEATH | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| US-20020123495-A1 | Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| WO-2002036565-A1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123495-A1 | Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | KCNJ11, HCN3, CACNA1E | ABCC9 143/4885ABCC8 169/4885KCNJ11 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.